SEC 13F Intelligence

Managers / Q3 2022 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$142M
Q3 2022
Positions
60
Filings on Record
39
2019–present window
Filed
Nov 28, 2022
amendment (RESTATEMENT)

Summary

Birchview Capital, LP reported $142M in U.S.-listed holdings across 60 positions for Q3 2022.

The portfolio is heavily concentrated: BMY alone accounts for 36.4% of reported value.

Compared with Q2 2022, the fund opened 6 new positions and exited 2.

Portfolio Metrics

Turnover
+7.4%
vs prior filed quarter
Top-10 Concentration
+70.5%
share of reported value
Largest Position
+36.4%
Bristol Myers Squibb
New / Exited
6 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 86.8%Other: 13.2%
  • Common Stock · 86.8% · $123M
  • Other · 13.2% · $19M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRPTSAREPTA THERAPEUTICS INCNEW+2.5K2.5K+$276,000$276,000
ATECALPHATEC HOLDINGS INCNEW+10.0K10.0K+$87,000$87,000
BIIBBIOGEN INCNEW+00+$0$0
AMARIN CORP PLCNEW+00+$0$0
AKBAAKEBIA THERAPEUTICS INCNEW+00+$0$0
VNDAVANDA PHARMACEUTICALS INCNEW+00+$0$0
TURNING POINT THERAPEUTICS INCSOLD OUT−8.0K0−$602,000$0
ZNTLZENTALIS PHARMACEUTICALS INCSOLD OUT−8.0K0−$225,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

60 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM36.43%$52M727.8K
2ELUTAZIYO BIOLOGICS INChistory →COM7.19%$10M1.42M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM6.37%$9M85.2K
4PROTHENA CORP PLCSHS5.08%$7M118.9K
5QDEL*QUIDELORTHO CORPhistory →COM3.09%$4M61.3K
6ACADACADIA PHARMACEUTICALS INChistory →COM2.87%$4M249.4K
7OVVOVINTIV INChistory →COM2.73%$4M84.2K
8ACCELERATE DIAGNOSTICS INCCOM2.41%$3M2.25M
9UTHUNITED THERAPEUTICS CORPhistory →COM2.21%$3M15.0K
10BIODESIX INCCOM2.12%$3M2.37M
11CLRUSDCONTINENTAL RESOURCES INChistory →COM1.82%$3M38.6K
12FHTXFOGHORN THERAPEUTICS INChistory →COM1.60%$2M264.8K
13BDQMALBIREO PHARMA INChistory →COM1.59%$2M117.0K
14BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM1.57%$2M14.7K
15HROWHARROW HEALTH INChistory →COM1.53%$2M180.0K
16MASI*MASIMO CORPhistory →COM1.52%$2M15.3K
17PHRPHREESIA INChistory →COM1.48%$2M82.7K
18GOSSGOSSAMER BIO INChistory →COM1.34%$2M159.1K
19VTYXUSDVENTYX BIOSCIENCES INChistory →COM1.11%$2M45.0K
20KPTIEURKARYOPHARM THERAPEUTICS INChistory →COM1.04%$1M269.3K
21HTDCORCEPT THERAPEUTICS INCCOM0.90%$1M50.0K
22INBXUSDINHIBRX INCCOM0.89%$1M70.4K
23CYTKCYTOKINETICS INCCOM0.85%$1M25.0K
24AVEO PHARMACEUTICALS INCCOM0.81%$1M140.0K
25ALKERMES PLCSHS0.79%$1M50.0K
26DCGODOCGO INCCOM0.77%$1M110.0K
27CCXIEURCHEMOCENTRYX INCCOM0.73%$1M20.0K
28ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.70%$995,000133.1K
29TSVT*2SEVENTY BIO INCCOM0.61%$871,00059.8K
30PXDEURPIONEER NATURAL RESOURCES COCOM0.58%$823,0003.8K
31APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.58%$820,00012.0K
32INARI MEDICAL INCCOM0.51%$726,00010.0K
33IMGNEURIMMUNOGEN INCCOM0.50%$717,000150.0K
34ARVNARVINAS INCCOM0.47%$667,00015.0K
35BLUEBIRD BIO INCCOM0.44%$620,00098.0K
364XC1KALVISTA PHARMACEUTICALS INCCOM0.41%$580,00040.0K
37IRTCIRHYTHM TECHNOLOGIES INCCOM0.35%$501,0004.0K
38GTHXEURG1 THERAPEUTICS INCCOM0.35%$500,00040.0K
39SILKUSDSILK ROAD MEDICAL INCCOM0.32%$450,00010.0K
40OPHTEURIVERIC BIO INCCOM0.32%$449,00025.0K
41NKTREURNEKTAR THERAPEUTICSCOM0.29%$410,000128.0K
42SOLENO THERAPEUTICS INCCOM0.29%$409,000245.1K
43AM6AMICUS THERAPEUTICS INCCOM0.28%$397,00038.0K
44KINIKSA PHARMACEUTICALS LTDCOM0.27%$385,00030.0K
45XENEXENON PHARMACEUTICALS INCCOM0.25%$361,00010.0K
46CGEMCULLINAN MANAGEMENT INCCOM0.23%$322,00025.1K
47XNCRXENCOR INCCOM0.23%$320,00012.3K
48PTGXPROTAGONIST THERAPEUTICS INCCOM0.23%$320,00038.0K
49SRPTSAREPTA THERAPEUTICS INCCOM0.19%$276,0002.5K
50BCRXBIOCRYST PHARMACEUTICALS INCCOM0.18%$252,00020.0K
51STOKSTOKE THERAPEUTICS INCCOM0.14%$193,00015.0K
52INFLARX NVCOM0.13%$185,00070.0K
53CNCEEURCONCERT PHARMACEUTICALS INCCOM0.09%$134,00020.0K
54ATECALPHATEC HOLDINGS INCCOM0.06%$87,00010.0K
55YIELD10 BIOSCIENCE INCCOM0.04%$56,00018.8K
56LSFLAIRD SUPERFOOD INCCOM0.04%$51,00028.0K
57ANGION BIOMEDICA CORPCOM0.04%$50,00054.4K
58CFRXEURCONTRAFECT CORPCOM0.02%$34,000200.0K
59SIENUSDSIENTRA INCCOM0.02%$26,00040.0K
60ASPIRA WOMEN'S HEALTH INCCOM0.02%$22,00060.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.